AB Corporate Bond ETF (NASDAQ:EYEG) Shares Cross Below Two Hundred Day Moving Average – Here’s Why

AB Corporate Bond ETF (NASDAQ:EYEG)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $35.43 and traded as low as $34.75. AB Corporate Bond ETF shares last traded at $34.77, with a volume of 60 shares.

AB Corporate Bond ETF Stock Down 0.2%

The company has a market capitalization of $27.82 million, a price-to-earnings ratio of -20.70 and a beta of 0.17. The business’s 50-day moving average is $35.11 and its 200-day moving average is $35.43. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01.

AB Corporate Bond ETF Cuts Dividend

The business also recently disclosed a monthly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Wednesday, July 1st were issued a $0.1358 dividend. This represents a c) annualized dividend and a dividend yield of 4.7%. The ex-dividend date of this dividend was Wednesday, July 1st. AB Corporate Bond ETF’s payout ratio is -102.98%.

Institutional Trading of AB Corporate Bond ETF

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in AB Corporate Bond ETF during the second quarter valued at approximately $232,000. Wealth Enhancement Advisory Services LLC lifted its holdings in AB Corporate Bond ETF by 32.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock valued at $5,634,000 after acquiring an additional 38,685 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in AB Corporate Bond ETF in the 4th quarter worth approximately $34,000. 64.16% of the stock is owned by institutional investors and hedge funds.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.